(-0.06%) 5 466.22 points
(-0.32%) 38 986 points
(0.29%) 17 770 points
(0.42%) $81.17
(-3.23%) $2.67
(-0.89%) $2 310.00
(-0.22%) $28.81
(1.61%) $1 002.30
(0.26%) $0.936
(0.68%) $10.68
(0.37%) $0.791
(-0.18%) $87.33
Live Chart Being Loaded With Signals
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma...
Stats | |
---|---|
本日の出来高 | 4.85M |
平均出来高 | 1.64M |
時価総額 | 210.38M |
EPS | $-0.0255 ( Q1 | 2023-05-11 ) |
Last Dividend | $0.150 ( 2012-12-18 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-2.85 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0510 (4.95%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-31 | Bradrick Brittany | Sell | 27 380 | Common Stock, $0.001 par value |
2023-07-31 | Bradrick Brittany | Sell | 86 301 | Stock Option (Right to Buy) |
2023-07-31 | Mcgahan Keith M | Sell | 195 485 | Common Stock, $0.001 par value |
2023-07-31 | Mcgahan Keith M | Sell | 386 057 | Common Stock, $0.001 par value |
2023-07-31 | Mcgahan Keith M | Sell | 778 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-41.93 |
Last 97 transactions |
Buy: 24 888 642 | Sell: 15 180 768 |
ボリューム 相関
Spectrum Pharmaceuticals 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Spectrum Pharmaceuticals 相関 - 通貨/商品
Spectrum Pharmaceuticals 財務諸表
Annual | 2022 |
収益: | $10.11M |
総利益: | $8.32M (82.28 %) |
EPS: | $-0.430 |
FY | 2022 |
収益: | $10.11M |
総利益: | $8.32M (82.28 %) |
EPS: | $-0.430 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.020 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.290 |
Financial Reports:
No articles found.
Spectrum Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.150 | 2012-12-18 |
Last Dividend | $0.150 | 2012-12-18 |
Next Dividend | $0 | N/A |
Payout Date | 2012-12-28 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.150 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0.150 | 1.02% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
18 Dec 2012 | $0.150 | 11 Dec 2012 | 20 Dec 2012 | 28 Dec 2012 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -1.400 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.334 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -1.193 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.71 | 0.800 | 1.449 | 1.159 | [1 - 3] |
quickRatioTTM | 2.31 | 0.800 | 1.124 | 0.899 | [0.8 - 2.5] |
cashRatioTTM | 1.347 | 1.500 | 3.63 | 5.44 | [0.2 - 2] |
debtRatioTTM | 0.275 | -1.500 | 5.42 | -8.12 | [0 - 0.6] |
interestCoverageTTM | -19.33 | 1.000 | -8.27 | -8.27 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.320 | 2.00 | -0.107 | -0.214 | [0 - 30] |
freeCashFlowPerShareTTM | -0.322 | 2.00 | -0.161 | -0.322 | [0 - 20] |
debtEquityRatioTTM | 1.105 | -1.500 | 5.58 | -8.37 | [0 - 2.5] |
grossProfitMarginTTM | 0.889 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.481 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -2.18 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.239 | 0.800 | -1.740 | -1.392 | [0.5 - 2] |
Total Score | -3.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.75 | 1.000 | -0.682 | 0 | [1 - 100] |
returnOnEquityTTM | -1.193 | 2.50 | -9.24 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.322 | 2.00 | -0.107 | -0.322 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.320 | 2.00 | -0.107 | -0.214 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.583 | 1.500 | 9.45 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -2.51 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.111 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。